AACR 2024: BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy
Used in the poster: Bispecific ADC Platform Summary: A fully human bispecific antibody (bsAb) targeting HER3 and MET was generated using RenLite® mice, known for…
Read more
AACR 2024: BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors
Used in the poster: BsAb Discovery Platform Summary: A novel bispecific antibody (BCG020) targeting both epidermal growth factor receptor (EGFR) and CD70 was developed to…
Read more
AACR 2024: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models
Used in the poster: Bispecific ADC Platform Summary: A bispecific antibody-drug conjugate (bsADC), BCG017-vcMMAE, targeting both PTK7 and EGFR demonstrated potent anti-tumor activity in various…
Read more
AACR 2024: Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses
Used in the poster: RenMabTM mice Summary: Immune checkpoint blockade therapy (ICT) is effective against tumors, but resistance due to regulatory T cell (Treg) infiltration…
Read more
AACR 2024: TIL analysis demonstrates different mechanisms underlying PD-1 resistance in animal models
Used in the poster: B-hPD-1/hPD-L1 mice Summary: Resistance to PD-1 immunotherapy presents a significant challenge in cancer treatment, often associated with alterations in the tumor…
Read more
AACR 2024: A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model
Used in the poster: BsAb Discovery Platform Summary: Folate receptor alpha (FOLR1) and MUC1 are overexpressed in various cancers, suggesting potential as therapeutic targets. A…
Read more
AACR 2024: Generation of humanized PD-1/PD-L1/CD94/NKG2A mice for evaluating novel combination therapies
Used in the poster: B-hPD-1/hPD-L1/hCD94/hNKG2A mice Summary: We created a quadruple humanized mouse model expressing NKG2A, CD94, PD-1, and PD-L1 to investigate potential combination therapies.…
Read more
AACR 2024: Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo
Used in the poster: B-hVEGFA mice Summary: Our study presents a novel humanized VEGFA model (B-hVEGFA mice) to investigate VEGFA-targeting therapies' efficacy in limiting cancer…
Read more
AACR 2024: Establishment of humanized CD3EDG/4-1BB mice for testing novel T cell engagers
Used in the poster: B-hCD3EDG/h4-1BB mice Summary: We developed a novel humanized B-hCD3EDG/h4-1BB mouse model by crossing mice expressing chimeric CD3E, CD3D, and CD3G with…
Read more
AACR 2024: Generation and validation of a novel humanized IL-31/IL-31RA/OSM/OSMR mouse model
Used in the poster: B-hIL31/hIL31RA/hOSM/hOSMR mice Summary: A novel preclinical mouse model was developed, expressing humanized IL-31, IL-31RA, OSM, and OSMR. This quadruple humanized model…
Read more
AACR 2024: Validation of humanized TL1A mice for advancing preclinical research
Used in the poster: B-hTL1A mice Summary: We generated a human TL1A knock-in (B-hTL1A mice) mouse model. Human TL1A gene expression in B-hTL1A mice was…
Read more
AET2023: Fully Human Anti-TIGIT Blocking Monoclonal Antibodies Demonstrate Potent Anti-Tumor Efficacy
Summary We obtained novel, differentiating, fully human anti-TIGIT clones with the following properties and activities • High binding affinity • Distinct epitopes from several clinical…
Read more